Casi Pharmaceuticals Inc Financials
This page shows Casi Pharmaceuticals Inc (CASI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Casi Pharmaceuticals Inc has an operating margin of -138.8%, meaning the company retains $-139 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -74.0% the prior year.
Casi Pharmaceuticals Inc's revenue declined 15.8% year-over-year, from $33.9M to $28.5M. This contraction results in a growth score of 0/100.
Casi Pharmaceuticals Inc has elevated debt relative to equity (D/E of 28.00), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.
Casi Pharmaceuticals Inc's current ratio of 1.09 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 23/100, which could limit financial flexibility.
While Casi Pharmaceuticals Inc generated -$29.2M in operating cash flow, capex of $223K consumed most of it, leaving -$29.4M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Casi Pharmaceuticals Inc passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Casi Pharmaceuticals Inc generates $0.74 in operating cash flow (-$29.2M OCF vs -$39.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Casi Pharmaceuticals Inc generated $28.5M in revenue in fiscal year 2024. This represents a decrease of 15.8% from the prior year.
Casi Pharmaceuticals Inc's EBITDA was -$38.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 69.7% from the prior year.
Casi Pharmaceuticals Inc generated -$29.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 46.0% from the prior year.
Casi Pharmaceuticals Inc reported -$39.3M in net income in fiscal year 2024. This represents a decrease of 45.6% from the prior year.
Casi Pharmaceuticals Inc earned $-2.56 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 26.7% from the prior year.
Casi Pharmaceuticals Inc held $13.5M in cash against $0 in long-term debt as of fiscal year 2024.
Casi Pharmaceuticals Inc had 15M shares outstanding in fiscal year 2024. This represents an increase of 15.8% from the prior year.
Casi Pharmaceuticals Inc's gross margin was 39.1% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 20.1 percentage points from the prior year.
Casi Pharmaceuticals Inc's operating margin was -138.8% in fiscal year 2024, reflecting core business profitability. This is down 64.8 percentage points from the prior year.
Casi Pharmaceuticals Inc's net profit margin was -137.6% in fiscal year 2024, showing the share of revenue converted to profit. This is down 58.0 percentage points from the prior year.
Casi Pharmaceuticals Inc invested $8.9M in research and development in fiscal year 2024. This represents a decrease of 9.6% from the prior year.
Casi Pharmaceuticals Inc invested $223K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 9.3% from the prior year.
CASI Income Statement
| Metric | Q4'24 | Q4'23 | Q4'22 | Q4'21 |
|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A | N/A |
| Operating Income | N/A | N/A | N/A | N/A |
| Interest Expense | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A |
| Net Income | N/A | N/A | N/A | N/A |
| EPS (Diluted) | N/A | N/A | N/A | N/A |
CASI Balance Sheet
| Metric | Q4'24 | Q4'23 | Q4'22 | Q4'21 |
|---|---|---|---|---|
| Total Assets | $53.7M-28.7% | $75.3M-21.8% | $96.2M-30.4% | $138.3M |
| Current Assets | $39.6M-33.3% | $59.3M-19.2% | $73.4M+18.5% | $62.0M |
| Cash & Equivalents | $13.5M-21.2% | $17.1M-63.7% | $47.1M+21.7% | $38.7M |
| Inventory | $5.3M-66.9% | $15.9M+158.7% | $6.1M+221.9% | $1.9M |
| Accounts Receivable | $15.3M+60.7% | $9.6M-26.4% | $13.0M+32.3% | $9.8M |
| Goodwill | N/A | N/A | N/A | N/A |
| Total Liabilities | $51.8M+1.4% | $51.1M-1.1% | $51.7M+70.3% | $30.3M |
| Current Liabilities | $36.5M+117.9% | $16.7M-1.6% | $17.0M+29.0% | $13.2M |
| Long-Term Debt | N/A | $18.9M | N/A | N/A |
| Total Equity | $1.9M-92.3% | $24.2M-45.8% | $44.6M-47.3% | $84.5M |
| Retained Earnings | -$700.1M-5.9% | -$660.8M-3.7% | -$637.2M-5.2% | -$605.6M |
CASI Cash Flow Statement
| Metric | Q4'24 | Q4'23 | Q4'22 | Q4'21 |
|---|---|---|---|---|
| Operating Cash Flow | N/A | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A |
| Financing Cash Flow | N/A | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A |
CASI Financial Ratios
| Metric | Q4'24 | Q4'23 | Q4'22 | Q4'21 |
|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A |
| Current Ratio | 1.09-2.5 | 3.55-0.8 | 4.32-0.4 | 4.70 |
| Debt-to-Equity | 28.00+27.2 | 0.78-0.4 | 1.16+0.8 | 0.36 |
| FCF Margin | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Casi Pharmaceuticals Inc's annual revenue?
Casi Pharmaceuticals Inc (CASI) reported $28.5M in total revenue for fiscal year 2024. This represents a -15.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Casi Pharmaceuticals Inc's revenue growing?
Casi Pharmaceuticals Inc (CASI) revenue declined by 15.8% year-over-year, from $33.9M to $28.5M in fiscal year 2024.
Is Casi Pharmaceuticals Inc profitable?
No, Casi Pharmaceuticals Inc (CASI) reported a net income of -$39.3M in fiscal year 2024, with a net profit margin of -137.6%.
What is Casi Pharmaceuticals Inc's earnings per share (EPS)?
Casi Pharmaceuticals Inc (CASI) reported diluted earnings per share of $-2.56 for fiscal year 2024. This represents a -26.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Casi Pharmaceuticals Inc's EBITDA?
Casi Pharmaceuticals Inc (CASI) had EBITDA of -$38.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Casi Pharmaceuticals Inc's gross margin?
Casi Pharmaceuticals Inc (CASI) had a gross margin of 39.1% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Casi Pharmaceuticals Inc's operating margin?
Casi Pharmaceuticals Inc (CASI) had an operating margin of -138.8% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Casi Pharmaceuticals Inc's net profit margin?
Casi Pharmaceuticals Inc (CASI) had a net profit margin of -137.6% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Casi Pharmaceuticals Inc's free cash flow?
Casi Pharmaceuticals Inc (CASI) generated -$29.4M in free cash flow during fiscal year 2024. This represents a -46.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Casi Pharmaceuticals Inc's operating cash flow?
Casi Pharmaceuticals Inc (CASI) generated -$29.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Casi Pharmaceuticals Inc's total assets?
Casi Pharmaceuticals Inc (CASI) had $53.7M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Casi Pharmaceuticals Inc's capital expenditures?
Casi Pharmaceuticals Inc (CASI) invested $223K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Casi Pharmaceuticals Inc spend on research and development?
Casi Pharmaceuticals Inc (CASI) invested $8.9M in research and development during fiscal year 2024.
How many shares does Casi Pharmaceuticals Inc have outstanding?
Casi Pharmaceuticals Inc (CASI) had 15M shares outstanding as of fiscal year 2024.
What is Casi Pharmaceuticals Inc's current ratio?
Casi Pharmaceuticals Inc (CASI) had a current ratio of 1.09 as of fiscal year 2024, which is considered adequate.
What is Casi Pharmaceuticals Inc's debt-to-equity ratio?
Casi Pharmaceuticals Inc (CASI) had a debt-to-equity ratio of 28.00 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Casi Pharmaceuticals Inc's return on assets (ROA)?
Casi Pharmaceuticals Inc (CASI) had a return on assets of -73.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Casi Pharmaceuticals Inc's cash runway?
Based on fiscal year 2024 data, Casi Pharmaceuticals Inc (CASI) had $13.5M in cash against an annual operating cash burn of $29.2M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Casi Pharmaceuticals Inc's Piotroski F-Score?
Casi Pharmaceuticals Inc (CASI) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Casi Pharmaceuticals Inc's earnings high quality?
Casi Pharmaceuticals Inc (CASI) has an earnings quality ratio of 0.74x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Casi Pharmaceuticals Inc?
Casi Pharmaceuticals Inc (CASI) scores 5 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.